High-quality evidence suggested a reduced risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma among US veterans with diabetes on GLP-1 RA therapy, and a lower incidence of multiple myeloma among GLP-1 RA users compared to insulin users. This evidence concerns the gene INS and plasma cell myeloma.